Search research articles
Contact Us
Filters
Showing results (491-500 of 548) with videos related to
Page
of 55
Sort By:
Genome Biology
|
April 6, 2023
Flexible and efficient handling of nanopore sequencing signal data with slow5tools
Hiruna Samarakoon, James M Ferguson, Sasha P Jenner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 1, 1986
Administration of MPTP to the common marmoset does not alter cortical cholinergic function
J Garvey, M Petersen, C M Waters, et al.
Biochemical Pharmacology
|
October 17, 1998
Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease
K S McNaught, P A Carrupt, C Altomare, et al.
Experimental Neurology
|
March 31, 2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
T Kanda, M J Jackson, L A Smith, et al.
Synapse (New York, N.Y.)
|
October 25, 2000
Expression and distribution of CYP2C enzymes in rat basal ganglia
A G Riedl, P M Watts, D C Douek, et al.
Annals of Neurology
|
December 1, 1994
Complex I, iron, and ferritin in Parkinson's disease substantia nigra
V M Mann, J M Cooper, S E Daniel, et al.
European Journal of Pharmacology
|
August 3, 1989
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437
P A Löschmann, P N Chong, M Nomoto, et al.
Nature
|
January 2, 1986
1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway
A J Bradbury, B Costall, A M Domeney, et al.
Biochemical Pharmacology
|
January 31, 1995
Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs
I Jeding, P J Evans, D Akanmu, et al.
Annals of Neurology
|
April 18, 1998
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
T Kanda, M J Jackson, L A Smith, et al.
Page
of 55
Search research articles
Search
Showing results (491-500 of 548) with videos related to
Sort By:
Page
of 55
Genome Biology
|
April 6, 2023
Flexible and efficient handling of nanopore sequencing signal data with slow5tools
Hiruna Samarakoon, James M Ferguson, Sasha P Jenner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 1, 1986
Administration of MPTP to the common marmoset does not alter cortical cholinergic function
J Garvey, M Petersen, C M Waters, et al.
Biochemical Pharmacology
|
October 17, 1998
Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease
K S McNaught, P A Carrupt, C Altomare, et al.
Experimental Neurology
|
March 31, 2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
T Kanda, M J Jackson, L A Smith, et al.
Synapse (New York, N.Y.)
|
October 25, 2000
Expression and distribution of CYP2C enzymes in rat basal ganglia
A G Riedl, P M Watts, D C Douek, et al.
Annals of Neurology
|
December 1, 1994
Complex I, iron, and ferritin in Parkinson's disease substantia nigra
V M Mann, J M Cooper, S E Daniel, et al.
European Journal of Pharmacology
|
August 3, 1989
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437
P A Löschmann, P N Chong, M Nomoto, et al.
Nature
|
January 2, 1986
1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway
A J Bradbury, B Costall, A M Domeney, et al.
Biochemical Pharmacology
|
January 31, 1995
Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs
I Jeding, P J Evans, D Akanmu, et al.
Annals of Neurology
|
April 18, 1998
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
T Kanda, M J Jackson, L A Smith, et al.
Page
of 55